![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VGLL3 |
Gene summary for VGLL3 |
![]() |
Gene information | Species | Human | Gene symbol | VGLL3 | Gene ID | 389136 |
Gene name | vestigial like family member 3 | |
Gene Alias | VGL-3 | |
Cytomap | 3p12.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8MV65 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389136 | VGLL3 | ATC11 | Human | Thyroid | ATC | 1.21e-05 | 5.21e-01 | 0.3386 |
389136 | VGLL3 | ATC13 | Human | Thyroid | ATC | 1.07e-15 | 2.76e-01 | 0.34 |
389136 | VGLL3 | ATC2 | Human | Thyroid | ATC | 3.07e-09 | 1.10e+00 | 0.34 |
389136 | VGLL3 | ATC3 | Human | Thyroid | ATC | 1.37e-10 | 6.53e-01 | 0.338 |
389136 | VGLL3 | ATC4 | Human | Thyroid | ATC | 4.13e-02 | 9.87e-02 | 0.34 |
389136 | VGLL3 | ATC5 | Human | Thyroid | ATC | 2.95e-12 | 3.02e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VGLL3 | SNV | Missense_Mutation | c.542N>T | p.Ala181Val | p.A181V | A8MV65 | protein_coding | tolerated(0.18) | benign(0.015) | TCGA-A8-A09T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
VGLL3 | SNV | Missense_Mutation | c.682N>T | p.Arg228Trp | p.R228W | A8MV65 | protein_coding | deleterious(0.04) | benign(0.353) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
VGLL3 | SNV | Missense_Mutation | c.683N>A | p.Arg228Gln | p.R228Q | A8MV65 | protein_coding | tolerated(0.42) | benign(0.058) | TCGA-D8-A1XO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
VGLL3 | insertion | Frame_Shift_Ins | novel | c.454_455insGAAAT | p.Thr152ArgfsTer62 | p.T152Rfs*62 | A8MV65 | protein_coding | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
VGLL3 | SNV | Missense_Mutation | rs200777627 | c.427C>T | p.Arg143Trp | p.R143W | A8MV65 | protein_coding | deleterious(0.01) | probably_damaging(0.919) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | novel | c.592N>A | p.Ala198Thr | p.A198T | A8MV65 | protein_coding | deleterious(0.03) | benign(0.049) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | c.385N>A | p.Leu129Ile | p.L129I | A8MV65 | protein_coding | tolerated(0.21) | possibly_damaging(0.549) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VGLL3 | SNV | Missense_Mutation | c.667N>G | p.His223Asp | p.H223D | A8MV65 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VGLL3 | SNV | Missense_Mutation | rs202199504 | c.716N>A | p.Arg239His | p.R239H | A8MV65 | protein_coding | tolerated(0.43) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | rs62622838 | c.722N>A | p.Arg241His | p.R241H | A8MV65 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |